Randomized Phase IIb Trial of DVC1-0101

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human fibroblast growth factor-2 (FGF-2) gene.

The primary objective of the current Phase IIb study is to investigate the clinical efficacy of DVC1-0101 (1x10\^9 ciu/leg, 5x10\^9 ciu/leg) in patients with IC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recombinant SeV-hFGF2/dF Injection for PAOD

NCT03668353

PAOD - Peripheral Arterial Occlusive Disease PAD Critical Limb Ischemia

UNKNOWN PHASE1

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

NCT02544204

Peripheral Arterial Disease

UNKNOWN PHASE2

Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication

NCT00117650

Intermittent Claudication Peripheral Vascular Disease Atherosclerosis

COMPLETED PHASE2

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

NCT01157143

Peripheral Arterial Occlusive Disease

COMPLETED PHASE1

Study of DU-176b Aged 80 Years or Older

NCT02801669

Atrial Fibrillation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DVC1-0101 is a gene therapy medicine to treat peripheral arterial disease (PAD) based on recombinant F-gene-deleted, non-transmissible Sendai virus (rSeV/dF) expressing human fibroblast growth factor-2 (FGF-2) gene. The previous Phase I/IIa study demonstrated no serious adverse event related to the administration, and suggested possible improvement of local blood flow and walking performance of PAD patients.

The primary objective of the current Phase IIb study is to investigate the clinical efficacy of DVC1-0101 (1x10\^9 ciu/leg, 5x10\^9 ciu/leg) in patients with IC. We also aim to examine the dose-response relationship using the rate of improvement in walking function as an indicator.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intermittent Claudication Peripheral Arterial Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo (0 ciu/limb)

Placebo control

Group Type PLACEBO_COMPARATOR

DVC1-0101

Intervention Type DRUG

The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

DVC1-0101 low dose (1x10^9 ciu/limb)

Low dose cohort

Group Type ACTIVE_COMPARATOR

DVC1-0101

Intervention Type DRUG

The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

DVC1-0101 high dose (5x10^9 ciu/limb)

High dose cohort

Group Type ACTIVE_COMPARATOR

DVC1-0101

Intervention Type DRUG

The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DVC1-0101

The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

rSeV/dF expressing human FGF-2 gene

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\) Meet criteria (1) to (5) below and are confirmed as such by at least 1 specialist qualified by the Japanese Society for Cardiovascular Surgery and at least 1 physician with deep experience Cardiovascular Intervention.

1. arteriosclerosis obliterans with stable symptoms, have intermittent claudication (ACD \< 260 m) and are able to walk on a treadmill
2. resting ankle-brachial pressure index \< 0.9
3. refuse revascularization, risk of revascularization may be greater than the benefit, or develop obliteration after revascularization
4. angiographic findings show patency from the abdominal aorta through to the proximal side of the external iliac artery
5. angiographic findings meet the above criterion (4), and have stenosis or obliteration under the femoropopliteal region with morphology defined as type C or D based on TASCII

2\) Administering cilostazol for at least 1 month and still meet criterion 1).

3\) Aged 30 and over.

4\) Either sex, either inpatients or outpatients.

5\) Able to give written consent for themselves.

Exclusion Criteria

1. Have ischemic ulcer.
2. Diagnosed with Buerger's disease.
3. Have a current or past history of life-threatening allergies.
4. Have been shown or are suspected to have cancer.
5. With concurrent proliferative intraocular neovascularization.
6. With poorly controlled diabetes mellitus.
7. With concurrent cardiac failure.
8. With untreated severe arrhythmia.
9. Have or are suspected to have interstitial pneumonia.
10. Have progressive hepatic disorders.
11. Have moderate or severe hepatic disorders. (1) aspartate aminotransferase or alanine aminotransferase \>2.5 times the upper limit (2) Prothrombin time is 14 seconds or longer (3) Serum bilirubin \>2.0 times the upper limit
12. Diagnosed with hepatic cirrhosis (classified as B or C on the Child-Pugh).
13. Have an inflammatory disease.
14. Treated with immunosuppressants or corticosteroids for the treatment of various inflammatory diseases or after organ transplantation.
15. Underwent extirpative surgery of a malignant tumor in the past 5 years.
16. Have had a cerebral hemorrhage or cerebral infarction in the past 6 months.
17. With blood diseases.
18. With moderate or severe renal dysfunction (CCr \<40 mL/min)
19. With alcohol or drug dependence.
20. Pregnant/lactating female, or who wish or are suspected to be pregnant.
21. Positive HIV antibodies.
22. Took part in any other clinical studies or research in the past 30 days.
23. Have allergic to the antibiotics and/or the Ribavirin.
24. Not permitted to participate in this study by the principal investigator or sub-investigator for any other reasons.

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No